"A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

6088Background: CABO is a multi-tyrosine kinase inhibitor targeting VEGF receptor kinase, RET, MET and AXL. We previously participated in a Phase I study which suggested activity in the RAI-refract... Click to show full abstract

Keywords: phase; cabo; rai; cabozantinib cabo; trial cabozantinib; phase trial

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended